Christopher A Maher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.
Year:
2025
Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.
Year:
2025
Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.
Year:
2025
Supplementary Figure S4. Summary of alterations in biologically relevant pathways found in pre-ARSI plasma cell-free DNA of 63 metastatic castration-resistant prostate cancer patients. ARSI, androgen receptor-signaling inhibitors.
Year:
2025
Supplementary Figure S9. Cell-free DNA methylation analysis of differentially accessible transcription factor binding sites. The box and whisker plots summarize methylation levels in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients after z-score transformation of the 10,000 TF binding sites corresponding to each of the top 20 TFs that are (A) most accessible and (B) least accessible in cfDNA from AR /enhancer altered lethal high-risk mCRPC patients. p values were calculated by the Mann-Whitney U test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S6. Kaplan–Meier survival analysis of the 43-patient mCRPC cohort that also underwent genome-wide EM-seq, according to (A,B) AR /enhancer alteration status and (C,D) median-split ichorCNA-based median tumor fraction. p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method. cfDNA, cell-free DNA; mCRPC; metastatic castration-resistant prostate cancer.
Year:
2025
Supplementary Figure S8. Transcription factor analysis in localized prostate cancer versus blood. Log2 fold change of the 20 TFs with most accessible and least accessible binding sites in plasma cell-free DNA (see Fig. 4E, Table S12 and Table S13) in localized prostate adenocarcinoma tumors from TCGA (n = 496) versus blood samples from GTEX (n = 337) (Methods). p value was calculated by Student’s t test. GTEX, Genotype-Tissue Expression project; TCGA, The Cancer Atlas Genome Atlas project; TF, transcription factor.
Year:
2025
Supplementary Figure S5. Kaplan-Meier survival analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment in 63 mCRPC patients according to (A,B) PTEN copy number loss status in cfDNA, (C,D) PTEN copy number loss or mutation in cfDNA, and (E,F) alteration in AR /Enhancer or PTEN in cfDNA. p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method. cfDNA, cell-free DNA; mCRPC; metastatic castration-resistant prostate cancer.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Collaborators (12)
Meng Zhang
Assistant Professor of Urology
Emory University
Oliver Sartor
Tulane University School of Medicine
David A. Quigley
Assistant Professor
University of California, San Francisco
Sean Park
Professor
Mayo Clinic Rochester
Jace Webster
Full Specialist
University of California, San Francisco
Peter Harris
Staff Scientist
Washington University in St. Louis
Aadel A. Chaudhuri
Washington University School of Medicine
Jacob Orme
Assistant Professor
Mayo Clinic
Pradeep Chauhan
Assistant Professor
Mayo Clinic
Felix Y. Feng
University of California
Fabrice Lucien
Assistant Professor
Mayo Clinic Minnesota
Russell K. Pachynski
Washington University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.